Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2025-09-26 Proxy Solicitation & In…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司关于召开2025年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2025 first extraordinary general meeting (临时股东大会) of shareholders for 哈药集团股份有限公司. It details the meeting date, voting methods, agenda items, and procedural instructions for shareholders. It does not contain financial statements or results but is an announcement of a shareholder meeting. This fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document is not a report itself but a meeting notice and proxy information.
2025-09-26 Chinese
哈药集团股份有限公司董事会授权管理层及总裁向董事会报告制度（2025年9月修订）
Governance Information Classification · 95% confidence The document is a detailed internal governance policy titled '董事会授权管理层及总裁向董事会报告制度' (Board Authorization to Management and President Reporting System) issued by 哈药集团股份有限公司. It outlines principles, procedures, and responsibilities related to board authorization to management and reporting by the president to the board. The content focuses on governance structure, delegation of authority, reporting requirements, and supervisory mechanisms. There are no financial statements, audit opinions, earnings data, or regulatory filings. It is not an announcement or a brief notice but a substantive governance document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-09-26 Chinese
哈药集团股份有限公司对外投资管理制度（2025年9月）
Governance Information Classification · 95% confidence The document is titled '哈药集团股份有限公司 对外投资管理制度' which translates to 'Hayao Group Co., Ltd. External Investment Management System'. It is a detailed internal policy document outlining the principles, decision-making authority, execution control, investment disposal, tracking, supervision, and other rules related to the company's external investments. It includes governance and procedural rules rather than financial results, audit opinions, or announcements. It is not a report of financial performance, earnings, or regulatory filing, nor is it an announcement or presentation. It is a governance/internal management document related to investment management policies. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 4214 characters, which is relatively short but contains substantive policy content, not a mere announcement or certification.
2025-09-26 Chinese
哈药集团股份有限公司信息披露管理制度（2025年9月修订）
Governance Information Classification · 95% confidence The document is titled '信息披露管理制度' (Information Disclosure Management System) of 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It details the company's internal policies and procedures for information disclosure, including legal compliance, responsibilities of directors and management, types of reports to be disclosed (annual, interim, quarterly, and temporary reports), confidentiality measures, and accountability for disclosure errors. It does not contain actual financial data, financial statements, or audit results. Instead, it is a governance and procedural document outlining how the company manages information disclosure obligations in compliance with Chinese securities laws and stock exchange rules. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-09-26 Chinese
哈药集团股份有限公司关于不再设立监事会并修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is a detailed announcement from 哈药集团股份有限公司 regarding the decision to no longer establish a supervisory board and the corresponding amendments to the company's Articles of Association (公司章程). It includes extensive legal and regulatory references, detailed changes to the Articles, and procedural information about corporate governance. The content is focused on governance structure changes and legal compliance rather than financial results or audit opinions. It is not a full annual or interim report, nor is it a simple announcement of a report publication. The document is too detailed and substantive to be a mere announcement or certification. It fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-09-26 Chinese
哈药集团股份有限公司外部信息使用人管理制度（2025年9月修订）
Governance Information Classification · 95% confidence The document is titled '外部信息使用人管理制度' (External Information User Management System) and contains detailed internal policies and procedures regarding the management, confidentiality, and legal compliance of information disclosure by 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It outlines the company's internal rules for handling and reporting information to external parties, confidentiality obligations, and legal responsibilities. There are no financial statements, earnings data, or report summaries present. The document is a governance-related internal policy document rather than a financial report or announcement. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The content aligns best with Governance Information (CGR), which covers internal rules, board structure, and governance practices.
2025-09-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.